Shares of Adma Biologics Inc. (NASDAQ:ADMA) have been given an average broker rating score of 2.33 (Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a hold rating and one has issued a strong buy rating on the company. Adma Biologics’ rating score has declined by 133% in the last 90 days as a result of various analysts’ upgrades and downgrades.
Analysts have set a one year consensus target price of $13.25 for the company and are expecting that the company will post ($0.40) EPS for the current quarter, according to Zacks. Zacks has also assigned Adma Biologics an industry rank of 105 out of 265 based on the ratings given to its competitors.
ADMA has been the topic of a number of analyst reports. Maxim Group decreased their price objective on Adma Biologics from $24.00 to $14.00 and set a “buy” rating on the stock in a research note on Monday, July 25th. Raymond James Financial Inc. lowered Adma Biologics from a “strong-buy” rating to a “market perform” rating in a research note on Monday, August 1st.
A number of hedge funds have recently modified their holdings of the company. Iguana Healthcare Management LLC acquired a new stake in shares of Adma Biologics during the second quarter worth about $744,000. Sabby Management LLC acquired a new stake in shares of Adma Biologics during the second quarter worth about $595,000. Guggenheim Capital LLC raised its stake in shares of Adma Biologics by 36.3% in the second quarter. Guggenheim Capital LLC now owns 29,747 shares of the company’s stock worth $177,000 after buying an additional 7,929 shares during the last quarter. UBS Oconnor LLC raised its stake in shares of Adma Biologics by 111.3% in the second quarter. UBS Oconnor LLC now owns 71,174 shares of the company’s stock worth $423,000 after buying an additional 37,497 shares during the last quarter. Finally, Spark Investment Management LLC raised its stake in shares of Adma Biologics by 126.8% in the second quarter. Spark Investment Management LLC now owns 31,300 shares of the company’s stock worth $186,000 after buying an additional 17,500 shares during the last quarter. 73.91% of the stock is currently owned by hedge funds and other institutional investors.
Adma Biologics (NASDAQ:ADMA) traded down 2.31% during mid-day trading on Thursday, hitting $6.77. 11,720 shares of the company were exchanged. The stock’s market cap is $87.24 million. Adma Biologics has a 12 month low of $4.15 and a 12 month high of $9.85. The firm has a 50 day moving average price of $6.18 and a 200 day moving average price of $6.71.
Adma Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Friday, August 12th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by $0.11. Adma Biologics had a negative net margin of 231.85% and a negative return on equity of 1,293.57%. Analysts anticipate that Adma Biologics will post ($1.76) EPS for the current fiscal year.
Adma Biologics Company Profile
ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.